Gambro Promises Corrective Actions To FDA, Makes Plans To Go Private
This article was originally published in The Gray Sheet
Executive Summary
Gambro says it will release new software for its Prisma hemodialysis machine by this summer to address safety concerns identified by FDA
You may also be interested in...
Gambro Renal Division Gets Second Warning Letter Of The Still-New Year
Two warning letters sent to Gambro in the past two months signal FDA's increasing alarm at how the firm's renal products division handles adverse event reports
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.